KR20210105872A - Fcrn 항체 조성물 및 이의 사용 방법 - Google Patents

Fcrn 항체 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR20210105872A
KR20210105872A KR1020217003706A KR20217003706A KR20210105872A KR 20210105872 A KR20210105872 A KR 20210105872A KR 1020217003706 A KR1020217003706 A KR 1020217003706A KR 20217003706 A KR20217003706 A KR 20217003706A KR 20210105872 A KR20210105872 A KR 20210105872A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
antibody
pharmaceutical composition
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020217003706A
Other languages
English (en)
Korean (ko)
Inventor
종리 장
그레고리 세인트. 루이스
에바 윌리엄스
나린더 싱
시데쉬 파틸
Original Assignee
모멘타 파머슈티컬스 인코포레이티드
그레고리 세인트. 루이스
종리 장
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모멘타 파머슈티컬스 인코포레이티드, 그레고리 세인트. 루이스, 종리 장 filed Critical 모멘타 파머슈티컬스 인코포레이티드
Publication of KR20210105872A publication Critical patent/KR20210105872A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020217003706A 2018-07-20 2019-07-19 Fcrn 항체 조성물 및 이의 사용 방법 Abandoned KR20210105872A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701467P 2018-07-20 2018-07-20
US62/701,467 2018-07-20
PCT/US2019/042597 WO2020023310A1 (en) 2018-07-20 2019-07-19 Compositions of fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20210105872A true KR20210105872A (ko) 2021-08-27

Family

ID=69180697

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217003706A Abandoned KR20210105872A (ko) 2018-07-20 2019-07-19 Fcrn 항체 조성물 및 이의 사용 방법

Country Status (16)

Country Link
US (1) US20210299255A1 (https=)
EP (1) EP3826641A4 (https=)
JP (1) JP7457704B2 (https=)
KR (1) KR20210105872A (https=)
CN (1) CN113301903A (https=)
AU (1) AU2019312139B2 (https=)
BR (1) BR112021001017A2 (https=)
CA (1) CA3106669A1 (https=)
CR (1) CR20210088A (https=)
EA (1) EA202190335A1 (https=)
IL (1) IL280280B2 (https=)
JO (2) JOP20210015A1 (https=)
MX (1) MX2021000790A (https=)
PH (1) PH12021550096A1 (https=)
SG (1) SG11202100420UA (https=)
WO (1) WO2020023310A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
KR102904658B1 (ko) 2017-12-13 2025-12-29 모멘타 파머슈티컬스 인코포레이티드 FcRn 항체 및 이의 사용 방법
CN113518783A (zh) 2018-07-20 2021-10-19 动量制药公司 FcRn抗体组合物
IL302516A (en) * 2020-11-06 2023-07-01 Janssen Biotech Inc FCRN antibodies and methods of using them
US20240182598A1 (en) * 2021-04-12 2024-06-06 Momenta Pharmaceuticals, Inc. Compositions and methods for treating pediatric myasthenia gravis
WO2024163894A1 (en) 2023-02-04 2024-08-08 Momenta Pharmaceuticals, Inc. Compositions and methods for treating hemolytic disease of the fetus and newborn
CN116539488B (zh) * 2023-05-11 2023-11-24 中国食品药品检定研究院 一种体外评价生物制品稳定性的方法、系统及设备
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
WO2025186787A1 (en) 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2026083290A1 (en) 2024-10-16 2026-04-23 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504499A (ja) * 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
ES2569409T3 (es) * 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
US20110027267A1 (en) * 2007-11-09 2011-02-03 Anaphore, Inc. Fusion Proteins of Mannose Binding Lectins for Treatment of Disease
WO2009124294A2 (en) 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20130323242A1 (en) * 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) * 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
RS64768B1 (sr) 2015-01-30 2023-11-30 Momenta Pharmaceuticals Inc Fcrn antitela i načini njihove upotrebe
WO2017015622A2 (en) * 2015-07-22 2017-01-26 Scholar Rock, Inc Gdf11 binding proteins and uses thereof
SMT202400004T1 (it) * 2016-07-29 2024-03-13 Momenta Pharmaceuticals Inc Anticorpi fcrn e loro metodi di utilizzo

Also Published As

Publication number Publication date
IL280280B2 (en) 2024-11-01
AU2019312139A1 (en) 2021-02-04
JP7457704B2 (ja) 2024-03-28
WO2020023310A1 (en) 2020-01-30
JP2021531346A (ja) 2021-11-18
CA3106669A1 (en) 2020-01-30
IL280280A (en) 2021-03-25
MX2021000790A (es) 2021-07-21
JOP20210015A1 (ar) 2021-01-19
PH12021550096A1 (en) 2022-03-28
EP3826641A4 (en) 2022-04-20
IL280280B1 (en) 2024-07-01
AU2019312139B2 (en) 2025-02-06
JOP20210014A1 (ar) 2021-01-19
US20210299255A1 (en) 2021-09-30
CR20210088A (es) 2021-09-02
BR112021001017A2 (pt) 2021-05-04
SG11202100420UA (en) 2021-02-25
EP3826641A1 (en) 2021-06-02
CN113301903A (zh) 2021-08-24
EA202190335A1 (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
KR20210105872A (ko) Fcrn 항체 조성물 및 이의 사용 방법
KR102921210B1 (ko) Fcrn 항체 조성물
KR102732284B1 (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
CN110167959A (zh) 用于监测对免疫检查点抑制剂pd1和pd-l1的抗体治疗的免疫测定和工程化蛋白
KR20140120938A (ko) Il-17 항체 제제
TW202039541A (zh) 多聚體ｔ細胞調節多肽及其使用方法
Yadav et al. Assessment and significance of protein–protein interactions during development of protein biopharmaceuticals
US20240424059A1 (en) Formulations for VEGF Receptor Fusion Proteins
JP2025142195A (ja) 抗ｐｄ－１／ｈｅｒ２二重特異性抗体を含む製剤及びその調製方法と使用
JP2023553209A (ja) 融合タンパク質の医薬製剤
KR20230026446A (ko) 재조합 항-pd-1 단일클론 항체를 위한 안정한 제형
EA046994B1 (ru) КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
BR112022025721B1 (pt) Formulação estável para anticorpo monoclonal anti-pd-1 recombinante
HK40098180A (zh) 用於融合蛋白的药物制剂
EA048285B1 (ru) Композиции антител против fcrn

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PC1904 Unpaid initial registration fee

St.27 status event code: A-2-2-U10-U14-oth-PC1904

St.27 status event code: N-2-6-B10-B12-nap-PC1904